MWNA
PRTK

Marshall Wace North America’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Marshall Wace North America’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-171,488
Closed -$3.26M – 1498
2017
Q1 		$3.26M Buy
+171,488
New +$2.7M 0.03% 488

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Marshall Wace North America's PRTK Position: Q2 2017 in Review

Marshall Wace North America sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q2 2017, closing a stake of 171,488 shares — an estimated $3.26M sold.

Marshall Wace North America first reported a position in PRTK in Q1 2017 and held it in 1 quarter. The position peaked at $3.26M in Q1 2017. 119 funds tracked by Wall St. Rank hold PRTK as of Q2 2017.

  • Marshall Wace North America reported no remaining Paratek Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Marshall Wace North America sold 171,488 Paratek Pharmaceuticals, Inc. shares in Q2 2017, an estimated $3.26M.
  • Marshall Wace North America first reported a position in Paratek Pharmaceuticals, Inc. in Q1 2017 and held it in 1 quarter.
  • Marshall Wace North America's Paratek Pharmaceuticals, Inc. position peaked at $3.26M in Q1 2017.
  • 119 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q2 2017.

Based on Marshall Wace North America's 13F filing for Q2 2017, filed 4 Aug 2017.